State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 130022, Changchun, China.
Zernike Institute for Advanced Materials, Nijenborgh 4, 9747, AG, Groningen, The Netherlands.
Angew Chem Int Ed Engl. 2019 Dec 16;58(51):18703-18709. doi: 10.1002/anie.201912399. Epub 2019 Nov 4.
Alzheimer's disease (AD) is a neurodegenerative disorder and the primary cause of age-related dementia. The etiology of AD is complex and has not been completely elucidated. Herein, we report that treatment with elastin-like polypeptides (ELPs), a component of the brain extracellular matrix (ECM), significantly increased the levels of AD-related amyloid-β peptides (Aβ) both in vitro and in vivo. Regarding the molecular mechanism(s), the upregulation of Aβ levels was related to increased proteolytic processing of the amyloid precursor protein. Furthermore, nesting tests demonstrated that the ELP-treated animals showed significant neurobehavioral deficits with cognitive impairment. These results suggest that the elastin is associated with AD-related pathological and behavioral changes. This finding presents a new aspect for Alzheimer's amyloidosis event and provides a great promise in developing ELP-based model systems to better understand the pathogenesis of AD.
阿尔茨海默病(AD)是一种神经退行性疾病,也是与年龄相关的痴呆的主要原因。AD 的病因复杂,尚未完全阐明。在此,我们报告弹性蛋白样多肽(ELP)治疗可显著增加体外和体内与 AD 相关的淀粉样β肽(Aβ)的水平。关于分子机制,Aβ水平的上调与淀粉样前体蛋白的蛋白水解加工增加有关。此外,嵌套测试表明,经 ELP 处理的动物表现出明显的神经行为缺陷和认知障碍。这些结果表明弹性蛋白与 AD 相关的病理和行为变化有关。这一发现为阿尔茨海默病淀粉样变性事件提供了一个新的方面,并为开发基于 ELP 的模型系统以更好地理解 AD 的发病机制提供了很大的希望。